NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine

{
  "id": "MLC-T-ONC-015400",
  "term": "NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/na-17-mage-3-a2-ny-eso-1-peptide-vaccine/"
}